Orion - Changes in company's own shares

Transfer of 137,000 own B-shares on 1 March 2013

ORION CORPORATION        STOCK EXCHANGE RELEASE 1 MARCH 2013 at  18.40    EET


In accordance with a decision by the Board of Directors, Orion Corporation has
on 1 March 2013 transferred altogether 137,000 Orion Corporation B-shares held
by the company as a share reward for earning periods 2010-2012 and 2012 to the
persons employed by the Orion Group and belonging to the Share-based Incentive
Plan of the Orion Group. The transfer is based on the authorisation by the
Annual General Meeting of 24 March 2010. The price per share of the transferred
shares is EUR 22.7936, which is the volume weighted average quotation of the
Orion Corporation B-share on 1 March 2013. Accordingly, the total transaction
price of the transferred shares is EUR 3,122,723.20.
After the share transfer, the total number of own B-shares held by Orion
Corporation is 188,991.

Orion Corporation has informed about the Share-based Incentive Plan in a stock
exchange release on 18 February 2010.



Orion Corporation



 Timo Lappalainen  Olli Huotari
 President and CEO SVP, Corporate Functions





Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orion.fi


Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company is continuously developing new drugs and
treatment methods. Pharmaceutical R&D focuses on central nervous system drugs,
oncology and critical care drugs, and Easyhaler® pulmonary drugs.

Orion's net sales in 2012 amounted to EUR 980 million and the company had about
3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.

[HUG#1682523]